Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry.

Maintenance of NEDA 2 and 3 criteria There was a clear trend that patients who initated DMTs for a minimum of 3 months in these index periods remained more frequently and longer free of disease activity according to NEDA 2 (no relapse, no 6mCDP) and NEDA 3 (no relapse, no 6MCDP, no MRI progression) criteria over the three periods of time ( figure 4 ).

also in 19,460 other papers